InflaRx N.V. (Nasdaq: IFRX) announced positive topline data on November 10, 2025, from its Phase 2a basket study evaluating INF904, an oral C5a receptor inhibitor, in patients with Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU). This announcement carries several significant implications for the company, patients, and the broader market.1
Key Data Highlights:
- Safety and Tolerability: INF904 demonstrated a positive safety profile with no signals of safety concern in either HS or CSU patients. Only mild (Grade 1) adverse events were reported as possibly related in a small number of patients.1
- Efficacy in HS: The study showed rapid and clinically meaningful reductions in abscesses and nodules (ANs) and draining tunnels (dTs) in HS patients. Robust HiSCR responses were observed, which continued to deepen four weeks after the treatment period, alongside substantial reductions in patient-reported pain scores. InflaRx suggests this demonstrates the potential for "biologic-like efficacy."1
- Efficacy in CSU: INF904 led to substantial reductions in the 7-day Urticaria Activity Score (UAS7), particularly in patients with severe disease, and improved disease control as measured by the Urticaria Control Test (UCT7).1 Specifically, the 60 mg BID dosing cohort achieved a UAS7 change from baseline of -13.7 points at Week 4, a level of activity that exceeds historically reported placebo levels and is within the range of existing approved CSU therapies.1
Implications for InflaRx (IFRX):
- Advancement of Pipeline: The positive results provide a strong rationale for the continued development of INF904 in both HS and CSU.1 InflaRx is prioritizing the initiation of a Phase 2b study for INF904 in HS in 2026 and plans to broaden the clinical program in CSU and other inflammatory disorders.1
- "Pipeline-in-a-Product" Potential: InflaRx views INF904 as a "pipeline-in-a-product" due to its potential applicability across multiple inflammatory diseases, underscoring its therapeutic promise.1
- Strategic Collaborations: The company is actively engaging in discussions with potential collaborators to expedite development, especially given the increased industry interest in the C5aR mechanism of action.1
- Competitive Positioning: As an orally administered C5aR inhibitor, INF904 could offer advantages over injectable therapies and potentially differentiate itself from other C5aR inhibitors by having minimal inhibition of CYP3A4/5 enzymes, which are important for drug metabolism.2
Implications for HS and CSU Patients and the Market:
- Addressing Unmet Needs: Both HS and CSU are chronic, debilitating conditions with significant unmet medical needs. HS affects an estimated 2% of the population, with its market projected to reach $15 billion by 2035.3 CSU also impacts a large patient population, with limited current treatment options for many.1
- Potential for a New Oral Treatment: INF904's oral formulation could offer a convenient and effective treatment option, potentially improving patient adherence and quality of life compared to injectable biologics.1
- Targeting Underlying Inflammation: By inhibiting the C5a receptor, INF904 aims to act on the fundamental inflammatory pathways driving these diseases.1
Investment Implications:
- Positive Catalyst: The positive topline data serves as a significant positive catalyst for InflaRx, potentially enhancing investor confidence and future valuation.
- Future Milestones: Investors will likely monitor the progression to Phase 2b for HS in 2026, further data presentations at scientific meetings, and any announcements regarding potential collaborations.1
- Market Opportunity: The substantial market sizes for both HS and CSU suggest considerable commercial potential for INF904 if it continues to progress successfully through clinical development and gains regulatory approval.3
Overall, the positive Phase 2a data for INF904 represents a crucial step forward for InflaRx and holds promise for patients suffering from HS and CSU, potentially offering a new, effective, and convenient oral treatment option.
